Roches Tecentriq® gets U.S. FDA nod for patients with breast cancer
Category: #healthcare  By Mateen Dalal  Date: 2019-03-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Roches Tecentriq® gets U.S. FDA nod for patients with breast cancer

The cancer immunotherapy drug could significantly reduce the risk of disease worsening or death (PFS) in patients by 40%.

Swiss healthcare conglomerate, Roche AG has recently announced that the U.S. FDA (Food and Drug Administration) has granted approval to its unresectable locally advanced or metastatic TNBC (triple-negative breast cancer) treatment Tecentriq® (atezolizumab) plus chemotherapy for patients whose tumors express PD-L1.

According to reliable sources, the indication’s approval comes in line to the accelerated approval based on progression-free survival (PFS). However, continued approval for this indication may depend upon the verification and description of clinical benefit in a confirmatory trial, cite sources.

According to a press release, Sandra Horning, MD, Chief Medical Officer & Head of Global Product Development, Roche, said that the FDA approval of its Tecentriq combination is an important treatment advance for people with PD-L1-positive, metastatic TNBC, a disease with high unmet medical needs.

She said that the Tecentriq® is the first cancer immunotherapy treatment to be approved for breast cancer, representing a meaningful step forward in the understanding of this disease.

Sources claim that the approval is based on reports attained from the Phase III IMpassion130 trial, which confirmed that Tecentriq plus nab-paclitaxel could significantly reduce the risk of disease worsening or death (PFS) by 40% compared with nab-paclitaxel alone in PD-L1-positive patients with unresectable locally advanced or metastatic TNBC who had not received prior chemotherapy for metastatic disease.

Reports claim that the most common Grade 3-4 side effects (≥2%) with Tecentriq plus nab-paclitaxel were reported to be low WBC (white blood cells), numbness or tingling in the feet and hands, neutrophil count decreased, feeling tired, low blood potassium level, low RBC (red blood cells), pneumonia and increased blood level of a liver enzyme (AST).

Furthermore, side effects (≥20 %) like hair loss, nausea, diarrhea, constipation, headache, cough, low WBC, decreased appetite and vomiting were also observed.

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
By Mateen Dalal

Shionogi & Co., Ltd., a Japan-based pharmaceutical company recently announced approval of drug c...

Disney stock soars as Disney+ reaches 10 million sign ups on day 1
Disney stock soars as Disney+ reaches 10 million sign ups on day 1
By Mateen Dalal

Reports confirm that Walt Disney Co shares climbed to a record high after the entertainment company ...

China’s Xpeng Motors secures $400m to expand electric car production
China’s Xpeng Motors secures $400m to expand electric car production
By Mateen Dalal

  Xpeng has already launched vehicles like G3 SUV and P7 sedan Xpeng and investors like Xia...